Publications by authors named "Lydia Walder"

Claim this Profile
C
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
Robert L Coleman, Solomon J Lubinga, Qin Shen, Lydia Walder, Mark Burton

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
Solomon J Lubinga, Lydia Walder, Mark Burton, Qin Shen

J Med Econ· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer.
Holly Guy, Carol Hawkes, Lydia Walder, Izabela A Malinowska, Divya Gupta

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Jinan Liu, Carol Hawkes, Lydia Walder, Chloe Spalding, Karin Travers

J Manag Care Spec Pharm· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, Paul Bessette, Sven Mahner

J Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
Holly Guy, Lydia Walder, Mark Fisher

Pharmacoeconomics· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Holly Guy, Lydia Walder, Mark Fisher

Pharmacoeconomics· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis